Open Access[68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence
Author(s) -
Mark A. Green,
Gary D. Hutchins,
Clinton D. Bahler,
Mark Tann,
Carla J. Mathias,
Wendy Territo,
Justin Sims,
Heather Polson,
David Alexoff,
William C. Eckelman,
Hank F. Kung,
James Fletcher
Publication year - 2019
Publication title -
molecular imaging and biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.846
H-Index - 68
eISSN - 1860-2002
pISSN - 1536-1632
DOI - 10.1007/s11307-019-01421-7
Subject(s) - prostate cancer , medicine , glutamate carboxypeptidase ii , nuclear medicine , biodistribution , dosimetry , positron emission tomography , cancer , positron emission tomography computed tomography , pharmacokinetics , prostate , radiology , in vivo , microbiology and biotechnology , biology
This study was undertaken to evaluate radiation dosimetry for the prostate-specific membrane antigen targeted [ 68 Ga]Ga-P16-093 radiopharmaceutical, and to initially assess agent performance in positron emission tomography (PET) detection of the site of disease in prostate cancer patients presenting with biochemical recurrence.